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Background: Venous thromboembolism (VTE) is a clinically significant complication that is well documented
among Caucasian cancer patients. However, evidence regarding VTE incidence and treatment among Asian cancer
patients is very limited. The objective of this study is to investigate the incidence, risk factors and management of
VTE among Taiwanese cancer patients.
Methods: Using Taiwan’s National Health Insurance Research Database, we identified 43,855 newly diagnosed
cancer patients between 2001 and 2008. Two alternative algorithms for identifying VTE event were explored to
better quantify a range of incidence rates of VTE in our cancer patients. Multivariable logistic regression models
were used to explore VTE risk factors.
Results: The incidence rates of VTE were 9.9 (algorithm 1) and 3.4 (algorithm 2) per 1,000 person-years, respectively.
The incidence rates were higher in certain cancers, particularly liver, pancreas, and lung. Significant risk factors for
VTE were site of cancer, prior history of VTE, chemotherapy and major surgeries. Long-term anticoagulant therapy
was initiated in 64.1% patients with VTE and 72.2% of them received warfarin alone. Approximately two-thirds of
patients with VTE received≤ 3 months of anticoagulant therapy.
Conclusion: Incidence of cancer-related VTE is lower among Taiwanese compared to Caucasian populations.
Nevertheless, risk factors for cancer-related VTE found in our study were consistent with current literature.
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Venous thromboembolism (VTE) is a significant compli-
cation among cancer patients. The incidence rates of
VTE among Caucasian cancer patients were reported to
be 4-20%. Cancer patients have 4- to 7-folds higher risk
for VTE than the general population [1,2]. In addition,
VTE-associated complications such as bleeding events,
post-thrombotic syndrome and recurrence of VTE
complicate the clinical management of cancer and
worsen patients’ quality of life [2]. Existing studies
have further linked VTE to a higher risk of 1-year
death post cancer diagnoses [3,4]. Several professional* Correspondence: fyshsiao@ntu.edu.tw
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unless otherwise stated.organizations, including American Society of Clinical
Oncology (ASCO) and National Comprehensive Can-
cer Network (NCCN), have therefore issued guidelines
regarding treatment and prophylaxis of VTE among
cancer patients [5-9]. However, these guidelines were
based on data mainly from Caucasian populations and
their applications in different racial/ethnic populations
are left unanswered.
In particular, available information on the epidemi-
ology of VTE among Asian cancer patients is very lim-
ited. Although observational studies have tried to fill this
knowledge gap, most existing studies were limited by
small sample sizes and specific cancer sites [10-15]. Dif-
ferent methodological approaches may have contributed
to dissimilar estimates of the incidence of VTE in the
Asian cancer patients as well. Furthermore, treatment
patterns for VTE among the Asian population may nothis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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study can help us to understand the incidence and treat-
ment of VTE among Asian cancer patients and optimize
clinical practice. Using a nationally-representative data-
set, we conducted a population-based cohort study to
investigate the epidemiology, risk factors, and clinical
profile of VTE among Taiwanese cancer patients. In




The data source of this population-based cohort study
was the Taiwan’s National Health Insurance research
database (NHIRD). The NHIRD is a nationwide database
comprising demographic data, clinical data, medical re-
source utilization data (outpatient and inpatient visits),
costs of services, and treatment patterns of more than
99% of the entire population (23 million) in Taiwan. All
traceable personal identifiers are removed from the data-
base to protect patient privacy. The database has been
described in detail elsewhere [16]. The NHIRD has been
maintained since 1997 and has been used to conduct
many population-level studies [16,17]. Three subsets of
the NHIRD, the Longitudinal Health Insurance Health
Insurance Database 2000 (LHID 2000), 2005 (LHID
2005) and 2010 (LHID 2010), which contains claims data
of one-million beneficiaries randomly selected from the
Registry of Beneficiaries of the NHIRD in 2000, 2005,
and 2010, respectively. The LHID 2000, LHID 2005, and
LHID 2010 thus include approximately 15% of the total
population in Taiwan. The databases used in this study
included all inpatient and outpatient medical claims of
the LHID 2000, LHID 2005 and LHID 2010 from Janu-
ary, 1999 to December, 2009.
Ethical statement
Because the identification numbers for all of the subjects
in the NHRID were encrypted to protect the privacy of
the individuals, this study was exempt from a full review
by the Institutional Review Board of the National Taiwan
University Hospital and informed consent was waived.
Study population
Newly diagnosed cancer patients defined by those who
have been first-ever hospitalized with a primary diagno-
sis of malignant disease (International Classification of
Diseases, Ninth Revision, Clinical Modification (ICD-9-
CM) code (ICD-9-CM codes: 140–208)) between January
1, 2001 and December 31, 2008 were identified. A two-
year wash-out period was applied to ensure their inci-
dent diagnoses of cancer. The date when a patient was
first hospitalized with a primary diagnosis of malignant
disease was defined as the index date. Cancer subtypesanalyzed in this study included head and neck (ICD-9-
CM codes: 140–149, 160–161), esophageal (150), stom-
ach (151), colorectum (153–154), liver (155), pancreas
(157), other abdominal (152, 156, 158–159), lung (162–
163), sarcoma (170–171), skin (172–173), breast (174–
175), endometrium and cervix (179–182), ovary (183),
prostate (185), testis (186), bladder (188), renal (189),
brain (191–192), thyroid (193), non-Hodgkin’s lymph-
oma (200, 202), Hodgkin’s lymphoma (201), multiple
myeloma (203), and leukemia (204–208). Patients were
excluded if their genders were unknown. Those who
had more than one primary diagnosis of malignant dis-
eases at index date were also excluded, for their cancer
sites cannot be categorized.
Identification of VTE
Two algorithms of VTE event were adopted in our study
to better quantify a range of incidence rates of VTE in
our cancer patients. VTE algorithm 1 was defined as a
hospital admission with diagnostic codes of VTE (ICD-
9-CM codes 415.1x, 451.xx, 452, and 453.xx). VTE algo-
rithm 2 was based on both the hospital admission with
diagnostic codes of VTE and managements of VTE
(prescription of intravenous or subcutaneous (IV/SC)
anticoagulants (unfractionated heparin (UFH) or low-
molecular-weight heparin (LMWH)) or reimbursement
codes of surgical thromboectomy) during the hospital
stay.
Comorbid diseases and potential risk factors for VTE
Comorbid diseases, including hypertension, heart failure,
ischemic heart disease, atrial fibrillation, renal insuffi-
ciency, liver disease, chronic lung disease, diabetes melli-
tus, stroke, rheumatologic diseases, varicose veins of
lower extremities, degenerative and paralytic neurologic
disease, peripheral vascular disease, anemia, arterial em-
bolism and obesity, were retrieved from both the out-
patient and inpatient medical claims for 1 year before or
during the index date using relevant ICD-9 CM codes. A
history of VTE was defined as being hospitalized with
VTE diagnosis within 2 years before the index date.
Potential risk factors of VTE, including pregnancy,
major surgery, hospitalization, cancer treatments (chemo-
therapy (including biologic therapy), radiation therapy,
hormone therapy, and combination therapy), major ex-
tremity trauma, major spine trauma, blood transfusion,
and infectious disease, were retrieved from inpatient or
outpatient medical claims from 3 months before the
VTE event to the end of follow-up date.
Treatment pattern of VTE
Among patients who had VTE events, we examined both
initial and long-term treatment of VTE. Initial treatment
patterns for patients who had VTE events were examined.
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followed to see their long-term anticoagulant treatment
pattern of VTE. Duration of long-term anticoagulant
treatment was calculated from the discharge date of first
hospitalization of VTE until the recurrence of VTE or
end of follow-up date and was categorized into ≤
3 months, 3–6 months, 6–12 months, and longer than
12 months.
Statistical analysis
Crude incidence rates of VTE for the entire cancer
patients and subgroups of patients categorized by sites
of cancer were calculated as the number of cases per
1,000 person-years. For VTE cases, the follow-up time
started from index date to the date of VTE event. For
patients without VTE event, the follow-up time started
from index date to the end of follow-up. Comparisons
between cancer patients with and without VTE were
performed using Student’s t-test for continuous variables
and chi-square or Fisher’s exact test for discrete variables.
Multivariable logistic regression models using stepwise
selection were carried out to identify risk factors for
VTE for the cohort defined using algorithm 2. To assess
the association between cancer site and risk of VTE, we
regrouped cancer sites as those with higher risk of VTE
(GI tracts (stomach, colorectum, pancreas, liver, and
esophagus), brain, lung, endometrium and cervix, ovary,
and kidney) [1], hematological malignant diseases (non-
Hodgkin’s lymphoma, Hodgkin’s lymphoma, multiple
myeloma, and leukemia) and other sites of cancer. Stat-
istical significance was set at p < 0.05 and all tests were
two-tailed. SAS software (Version 9.2; SAS Institute
Inc., Cary, NC, USA) and Microsoft Office Excel 2010
were used in this study for the claims data conversion
and analysis.
Results
Baseline characteristics of study cohort and incidence rate
of VTE
We identified 43,855 newly diagnosed cancer patients
between January 1, 2001 and December 31, 2008. The
mean age (± SD) of the study cohort was 59.5 years
(±15.9 years). Slightly more than half of them (52.7%)
were men and nearly forty percent (41.9%) of patients
were aged 65 years and older. Colorectal cancer (14.7%)
was the most frequently diagnosed cancer in our study
cohort, followed by breast cancer (13.8%), liver cancer
(12.0%), head and neck cancer (10.0%), and lung cancer
(9.5%).
Among 43,855 newly diagnosed cancer patients, hos-
pital admissions for VTE (algorithm 1) were identified
in 1,388 patients (3.2%) during or after index date. As
shown in Table 1, the overall incidence rate of VTE
(algorithm 1) was 9.88 per 1,000 person-years. Theincidence rates of VTE were higher in men than women
(13.56 vs. 6.61 per 1,000 person-years). The incidence
rates of VTE were higher in certain cancers, particularly
cancer of liver (68.23 per 1,000 person-years), pancreas
(27.83 per 1,000 person-years), lung (17.22 per 1,000
person-years), multiple myeloma (10.56 per 1,000 person-
years), and non-Hodgkin’s lymphoma (9.32 per 1,000
person-years). Taken together, these five cancers accounted
for 67.6% of the VTE cases.
Hospital admissions for VTE (algorithm 2) were iden-
tified in 473 patients (1.1%) during or after index date.
The overall incidence rate of VTE (algorithm 2) was
3.35 per 1,000 person-years; slightly higher in men than
women (3.89 vs. 2.86 per 1,000 person-years) (Table 1).
The incidence rates of VTE were higher in certain can-
cers, particularly cancer of pancreas (16.05 per 1,000
person-years), lung (10.20 per 1,000 person-years), liver
(9.06 per 1,000 person-years), multiple myeloma (7.92 per
1,000 person-years), and sarcoma (5.08 per 1,000 person-
years). Taken together, these five cancers accounted for
42.3% of all VTE cases.
Clinical characteristics of VTE events
Most VTE events (VTE algorithm 1) (53.5%) occurred
within 90 days after index date, with 35.8% of VTE
events occurring on the index date (Table 2). Median
time-to-VTE was 70 days (range, 0–3,124 days). Among
patients who experience a VTE, the cumulative occur-
rence of VTE within 30, 90, 180, 270, and 365 days after
index date were 42.9%, 53.5%, 61.8%, 66.3%, and 70.8%,
respectively. Among patients hospitalized for VTE
(algorithm 2), 59.4% of VTE events occurred within
1 year after index date, with 18.0% of VTE events occur-
ring on the index date (Table 2). Median time-to-VTE
was 222 days (range, 0–3,124 days). Cumulative occur-
rence of VTE within 30, 90, 180, 270, and 365 days after
index date were 25.2%, 39.8%, 47.8%, 53.9, and 59.4%,
respectively.
Anatomic distribution of VTE is shown in Table 3.
Among 1,388 patients with VTE (algorithm 1), 9.7% of
patients had pulmonary embolism (PE) (with or without
venous thrombosis) and 90.4% of patients had venous
thrombosis. Among those with venous thrombosis,
52.9% had intra-abdominal thrombosis (thrombosis of
renal, hepatic, or portal vein) and 27.7% had thrombosis
of other unspecified site. Among 473 patients with VTE
(algorithm 2), 16.1% had PE (with or without venous
thrombosis) and 80.7% had venous thrombosis. Among
those with venous thrombosis, 19.0% had intra-abdominal
thrombosis and 53.9% had thrombosis of unspecified site.
Baseline characteristics and risk factors for VTE
The mean age (± SD) of cancer patients with VTE
(algorithm 2) was 60.9 years (±14.3 years), which was
Table 1 Site of cancer and associated incidence rate of VTE among all cancer patients



















All patients 43,855 1,388 3.2 140,524 9.88 473 1.1 141,304 3.35
Male 23,115 896 3.9 66,063 13.56 259 1.1 66,571 3.89
Female 20,740 492 2.4 74,461 6.61 214 1.0 74,734 2.86
Site of cancer
Liver 5,272 764 14.5 11,197 68.23 105 2.0 11,593 9.06
Pancreas 618 19 3.1 683 27.83 11 1.8 685 16.05
Lung 4,159 121 2.9 7,025 17.22 72 1.7 7,058 10.20
Multiple myeloma 183 4 2.2 375 10.65 3 1.7 379 7.92
Non-Hodgkin’s
lymphoma
1,011 30 3.0 3,219 9.32 15 1.5 3,248 4.62
Leukemia 689 16 2.3 1,740 9.20 4 0.6 1,758 2.28
Renal 1,303 33 2.5 4,655 7.09 16 1.2 4,686 3.41
Sarcoma 458 12 2.6 1,761 6.82 9 2.0 1,773 5.08
Stomach 2,231 40 1.8 6,110 6.55 22 1.0 6,123 3.59
Ovary 668 15 2.3 2,390 6.28 11 1.7 2,405 4.57
Colorectum 6,462 112 1.7 22,452 4.99 69 1.1 22,502 3.07
Esophageal 761 6 0.8 1,239 4.84 4 0.5 1,240 3.23
Brain 522 7 1.3 1,559 4.49 5 1.0 1,562 3.20
Endometrium and cervix 2,327 43 1.9 10,024 4.29 31 1.3 10,055 3.08
Prostate 1,943 29 1.5 7,218 4.02 20 1.0 7,232 2.77
Bladder 1,723 23 1.3 6,477 3.55 14 0.8 6,484 2.16
Testis 119 2 1.7 582 3.44 0 0.00 590 0.00
Other abdominal 671 9 1.3 1,681 3.36 4 0.6 1,685 2.37
Skin 898 11 1.2 3,426 3.21 6 0.7 3,436 1.75
Hodgkin’s lymphoma 85 1 1.2 342 2.92 0 0.00 348 0.00
Head and neck 4,390 40 0.9 14,922 2.68 20 0.5 14,955 1.34
Breast 6,035 45 0.8 25,438 1.77 29 0.5 25,485 1.14
Thyroid 1,327 6 0.5 6,009 1.00 3 0.2 6,020 0.50
Abbreviations: p-y, person-years.
aFor VTE cases, person-years were calculated from index date to the date of first hospitalization for VTE during or after cancer diagnosis. For patients without VTE
event, person-years were calculated from index date until end of follow-up date.
#VTE algorithm 1 was defined as a hospital admission with diagnostic codes of VTE (ICD-9-CM codes: 415.1x, 451.xx, 452, and 453.xx).
&VTE algorithm 2 was based on both the hospital admission with diagnostic codes of VTE and managements of VTE (prescription of intravenous or subcutaneous
(IV/SC) anticoagulants (unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH)) or reimbursement codes of surgical thromboectomy) during the
hospital stay.
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from cancer patients without VTE (59.5 ± 15.9 years)
(Table 4). Compared with cancer patients without VTE,
more cancer patients with VTE had prior histories of
VTE within the 2 years before index date (1.1% vs. 0.2%,
p < 0.0001). Furthermore, patients with VTE were
significantly more likely to have comorbid diseases
(including hypertension, heart failure, ischemic heart
disease, renal insufficiency, liver disease, rheumatologic
diseases, arterial embolism, obesity, and varicose veins oflower extremities) than patients without VTE. Compared
with patients without VTE, more patients with VTE
received major surgery, active therapy, and G-CSF, or
were diagnosed with infectious diseases within
3 months before/during the VTE event. Hospital
admission was more frequent in patients with VTE
(60.0% vs. 32.1%, p < 0.0001). Among patients who re-
ceived active therapy, more patients with VTE received
chemotherapy (38.5% vs. 11.9%, p < 0.0001) and
combination therapy (4.2% vs. 1.2%, p < 0.0001), but more
Table 2 Time-to-VTE after cancer diagnosis among all cancer patients
VTE algorithm 1# (N = 1,388) VTE algorithm 2& (N = 473)
Time-to-VTE Patient no. (%) Cumulative rate of VTE (%) Patient no. (%) Cumulative rate of VTE (%)
0 days 497 (35.8) 35.8 85 (18.0) 18.0
1 – 30 days 98 (7.1) 42.9 34 (7.2) 25.2
31 – 90 days 147 (10.6) 53.5 69 (14.6) 39.8
91 – 180 days 115 (8.3) 61.8 38 (8.0) 47.8
181 – 270 days 63 (4.5) 66.3 29 (6.1) 53.9
271 – 365 days 62 (4.5) 70.8 26 (5.5) 59.4
366 – 545 days 70 (5.0) 75.8 32 (6.8) 66.2
546 – 761 days 75 (5.4) 81.2 33 (7.0) 73.2
>731 days* 261 (18.8) 100.0 127 (26.9) 100.0
*The last observed events occurred 3,124 days after index date.
#VTE algorithm 1 was defined as a hospital admission with diagnostic codes of VTE (ICD-9-CM codes 415.1x, 451.xx, 452, and 453.xx).
&VTE algorithm 2 was based on both the hospital admission with diagnostic codes of VTE and managements of VTE (prescription of intravenous or subcutaneous
(IV/SC) anticoagulants (unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH)) or reimbursement codes of surgical thromboectomy) during the
hospital stay.
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3.6%, p < 0.0001).
The results of multivariable logistic regression analysis
showed that risk factors for VTE were primary cancer
sites of GI, brain, lung, gynecologic, and renal, prior
history of VTE, hypertension, arterial embolism, obesity,
and rheumatologic diseases (Table 5). In addition, major
thoracic, abdominal, and urogenital surgery, chemother-
apy, and combination therapy were significantly associ-
ated with higher risk of VTE. In contrast, blood
transfusion was associated with reduced risk of VTE.Table 3 Anatomic distribution of VTE among all cancer patien
Sites
Pulmonary embolism
Pulmonary embolism and venous thrombosis
Thrombosis of extremities
Thrombosis of vena cava
Thrombosis of renal vein, hepatic vein or portal vein
Thrombosis of unspecified site
Superficial venous thrombosis
Multiple thrombotic sites
a715 patients had portal vein thrombosis, 12 patients had hepatic vein thrombosis,
b86 patients had portal vein thrombosis, 2 patients had hepatic vein thrombosis, 2
c16 patients had concomitant thrombosis of vena cava and intra-abdominal venous
site, and 3 patients had concomitant thrombosis of vena cava, intra-abdominal ven
d4 patients had concomitant thrombosis of vena cava and intra-abdominal venous,
other unspecified site.
#VTE algorithm 1 was defined as a hospital admission with diagnostic codes of VTE
&VTE algorithm 2 was based on both the hospital admission with diagnostic codes
(IV/SC) anticoagulants (unfractionated heparin (UFH) or low-molecular-weight hepa
hospital stay.Treatment pattern of VTE
Among 1,388 patients hospitalized for VTE (algorithm
1), only 33.6% of patients received anticoagulant ther-
apy or surgical thromboectomy during the hospital
stay. Only 7.9% of patients with thrombosis of hepatic,
portal, or renal vein alone (n = 734) received manage-
ment of VTE. In contrast, excluding patients with super-
ficial vein thrombosis (n = 4), anticoagulation or surgical
thromboectomy was performed in 62.9% of patients with
other sites of venous thrombosis or PE (n = 650). Among
cancer patients with VTE events (algorithm 2), 1.5% ofts
VTE algorithm 1# VTE algorithm 2&
(N = 1,388) (N = 473)
Patient no. (%) Patient no. (%)
118 (8.5) 76 (16.1)
16 (1.1) 15 (3.2)
73 (5.3) 19 (4.0)
38 (2.7) 12 (2.5)
734 (52.9)a 90 (19.0)b
384 (27.7) 255 (53.9)
4 (0.3) 0 (0.0)
21 (1.5)c 6 (1.3)d
7 patients had thrombosis of renal vein.
patients had thrombosis of renal vein.
, 1 patient had concomitant thrombosis of extremities and other unspecified
ous and other unspecified site.
and 2 patients had concomitant thrombosis of intra-abdominal venous and
(ICD-9-CM codes 415.1x, 451.xx, 452, and 453.xx).
of VTE and managements of VTE (prescription of intravenous or subcutaneous
rin (LMWH)) or reimbursement codes of surgical thromboectomy) during the
Table 4 Baseline characteristics of cancer patients with or without VTE
Patients without VTE VTE (algorithm 2&) P-value
N = 43,382 N = 473
Mean age (years) 59.52 ± 15.92 60.86 ± 14.26 0.0440*
No. % No. %
Age groups (years) 0.0005*
≤18 502 1.2 1 0.2
19 – 40 4,431 10.2 36 7.6
41 – 60 16,847 38.8 179 37.9
61 – 80 18,183 41.9 227 48.0
≥81 3,419 7.9 30 6.3
Gender 0.3695
Male 22,856 52.7 259 54.8
Female 20,526 47.3 214 45.2
Prior history of VTE 67 0.2 5 1.1 0.0011*
Hypertension 15,981 36.8 223 47.2 <0.0001*
Heart failure 1,793 4.1 31 6.6 0.0087*
Ischemic heart disease 6,005 13.8 86 18.2 0.0066*
Atrial fibrillation 649 1.5 9 1.9 0.4522
Renal insufficiency 3,270 7.5 53 11.2 0.0027*
Chronic lung disease 8,211 18.9 95 20.1 0.5229
Diabetes mellitus 7,874 18.2 97 20.5 0.1861
Stroke 2,690 6.2 30 6.3 0.8988
Degenerative & paralytic neurologic disease 3,665 8.5 47 9.9 0.2474
Rheumatologic diseases 573 1.3 12 2.5 0.0218*
Liver disease 7,959 18.4 119 25.2 0.0001*
Arterial embolism 165 0.4 7 1.5 0.0028*
Anemia 5,179 11.9 62 13.1 0.4354
Varicose veins of lower extremities 170 0.4 5 1.1 0.0418*
Peripheral vascular disease 515 1.2 9 1.9 0.1543
Pregnancy 74 0.2 2 0.4 0.1979
Infectious diseases 15,809 36.4 242 51.2 <0.0001*
Major trauma before VTE event 1260 2.9 18 3.8 0.2465
Major spine trauma 426 1.0 6 1.3 0.4775
Major extremity trauma 861 2.0 12 2.5 0.3924
Major surgery before VTE event 10,152 23.4 286 60.5 <0.0001*
CNS 457 1.1 8 1.7 0.1779
Thorax 4,706 10.9 158 33.4 <0.0001*
Abdomen 6,094 14.1 167 35.3 <0.0001*
Urogenital 1,397 3.2 43 9.1 <0.0001*
Orthopedic 164 0.4 1 0.2 1.0000
Hospitalization 13,909 32.1 284 60.0 <0.0001*
Blood transfusion 3,665 8.5 49 10.4 0.1376
Active therapy 9,079 20.9 221 46.7 <0.0001*
Chemotherapy only 5,151 11.9 182 38.5 <0.0001*
Radiation only 214 0.5 2 0.4 1.0000
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Table 4 Baseline characteristics of cancer patients with or without VTE (Continued)
Hormone therapy only 3,180 7.3 17 3.6 0.0020*
Combination therapy 534 1.2 20 4.2 <0.0001*
Use of erythropoietin stimulating agent (ESA) 828 1.9 9 1.9 0.9926
Use of granulocyte colony-stimulating factor (GCSF) 1,282 3.0 41 8.7 <0.0001*
Thalidomide therapy 27 0.1 0 0.0 1.0000
Obesity 146 0.3 5 1.1 0.0243*
*p-value < 0.05.
&VTE algorithm 2 was based on both the hospital admission with diagnostic codes of VTE and managements of VTE (prescription of intravenous or subcutaneous
(IV/SC) anticoagulants (unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH)) or reimbursement codes of surgical thromboectomy) during the
hospital stay.
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received LMWH/ UFH for initial treatment of VTE.
Patients with VTE (algorithm 2) were followed to
analyze the long-term treatment of VTE. Among 473
patients with VTE (algorithm 2), 58 patients (12.3%) did
not have any medical claim in the database after the
VTE event. We therefore explored patterns of long-term
anticoagulant treatment in the remaining 415 patients.
Overall, long-term anticoagulant therapy was initiated in
64.1% of patients (Table 6). Among them, 46.3% of
patients received warfarin alone and 9.6% of patients re-
ceived LMWH at any time. The median duration of anti-
coagulant therapy was 66 days (range, 2–1,442 days).
Among these patients, 58.7%, 18.4%, 13.5% and 9.4% of
them received ≤ 3 months, 3–6 months, 6–12 monthsTable 5 Multivariable logistic regression: risk factors for
VTE among all cancer patients
Variable Odds ratio 95% Cl
Cancer sites
Low risk (reference)
High risk 1.63 1.31 - 2.02
Hematologic 1.26 0.79 - 2.00
Prior history of VTE 4.32 1.60 - 11.66
Comorbid diseases
Hypertension 1.41 1.17 - 1.70
Arterial embolism 2.96 1.31 - 6.67
Obesity 2.88 1.13 - 7.35
Rheumatologic diseases 1.90 1.05 - 3.43
Potential risk factors
Surgery
Thoracic 2.35 1.91 - 2.89
Abdominal 1.99 1.62 - 2.45
Urogenital 2.12 1.52 - 2.94
Chemotherapy 3.61 2.95 - 4.41
Combination therapy 4.95 3.08 - 7.96
Blood transfusion 0.57 0.42 - 0.77and ≥ 12 months of long-term anticoagulant therapy,
respectively.
Discussion
Using the NHI research database, we examined the inci-
dence, risk factors and clinical characteristics of VTE
among patients with different cancer types over a period
of 9 years. The major strength of our study is that we re-
port population-based rates for VTE incidence and
treatment patterns in an Asian population. Two alterna-
tive algorithm were used to capture VTE diagnosis codes
and managements of VTE during the hospital stay. The
second algorithm was similar to the outcome definition
used in previous population-based studies [18-20]. To
avoid serious underestimation of the incidence rate of
VTE among cancer patients, we also included patients
who hospitalized for VTE only (algorithm 1). By adopt-
ing two VTE algorithms in our study, we believe we
could provide crude incidence rates of accidentally de-
tected VTE and clinical symptomatic VTE.
In our study, 1.1% to 3.2% of all newly diagnosed can-
cer patients were hospitalized for VTE events, based on
two algorithms of VTE. Our study showed a higher inci-
dence of VTE among the non-Caucasian cancer patients,
which is consistent with Yu et al. [20]. The incidence
rate of VTE is 21- to 62- folds among cancer patients
than the general population in Taiwan (15.9 per 100,000
person-years) [19]. Nevertheless, the VTE incidence is
significantly lower than reports among Caucasian popu-
lations [21-23]. Among Caucasian patients with cancer,
the estimated incidence rate of VTE ranges from 0.6% to
12.1% [24-31]. The incidence rate in our study is lower
than reported rates of Cronin-Fenton et al. [29] and
Khorana et al. [28] among Caucasian populations.
There is convincing evidence that the risk of VTE in-
creases in proportion to the number of predisposing fac-
tors [32,33]. Identification of risk factors can help us to
identify cancer patients with higher risk for VTE and
optimize the prophylaxis of VTE. In our study, an in-
creased risk of VTE was associated with cancer site,
prior history of VTE, arterial embolism, hypertension,
obesity, major surgery, chemotherapy, and combination
Table 6 Initial and long-term treatment of VTE among all cancer patients
VTE (algorithm 1#) VTE (algorithm 2&)
(N = 1,388) (N = 473)
Initial treatment Patient no. (%) Patient no. (%)
Thromboectomy 7 (0.5) 7 (1.5)
Low molecular weight heparin (LMWH)
LMWH alone 58 (4.2) 64 (13.5)
LMWH+warfarin 143 (10.3) 148 (31.3)
Unfractioned heparin (UFH)
UFH alone 79 (5.7) 115 (24.3)
UFH + warfarin 72 (5.2) 77 (16.3)
UFH + LWMH
UFH + LMWH 16 (1.1) 17 (3.6)
UFH + LMWH+warfarin 43 (3.1) 45 (9.5)
Warfarin only 49 (3.5) 0 (0.00)
No anticoagulation therapy 921 (66.4) 0 (0.00)
Long-term treatment Patient no. (%) Patient no. (%)
LMWH alone - 24 (5.8%)
UFH alone - 24 (5.8%)
Warfarin alone - 192 (46.3%)
LMWH+warfarin - 13 (3.1%)
UFH + warfarin - 10 (2.4%)
LMWH and UFH - 3 (0.7%)
No anticoagulant therapy - 149 (35.9%)
#VTE algorithm 1 was defined as a hospital admission with diagnostic codes of VTE (ICD-9-CM codes 415.1x, 451.xx, 452, and 453.xx).
&VTE algorithm 2 was based on both the hospital admission with diagnostic codes of VTE and managements of VTE (prescription of intravenous or subcutaneous
(IV/SC) anticoagulants (unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH)) or reimbursement codes of surgical thromboectomy) during the
hospital stay.
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among cancer patients [25,27,28,31,34-36]. Rheumatologic
diseases were first identified as an independent risk
factor for VTE among cancer patients in our study.
Recent epidemiological studies among general popula-
tion also suggested that certain rheumatologic diseases,
including rheumatic arthritis (RA), dermatomyositis/
polymyositis and systemic lupus erythematous (SLE)
were associated with increased risk of VTE [37,38].
Thrombosis of portal vein is common in our study. In
our study, 51.5% (algorithm 1) and 18.2% (algorithm 2) of
patients with VTE had portal vein thrombosis alone. More
than 80% of the portal vein thrombosis occurred in
patients with liver cancer. Consistent with previous studies
in Korea [12,13], we found that most patients with throm-
bosis of renal, portal or hepatic veins did not received anti-
coagulant treatment in clinical practice. Liver cancer is a
well-known risk factor for portal vein thrombosis
[39,40]. The high prevalence of liver cancer in Taiwan
[41] may result in the high prevalence of portal vein
thrombosis in our study cohort. However, there is norandomized trial to guide the use of anticoagulation in
this situation [39,42]. Given the common prevalence of
portal vein thrombosis, further studies are needed to
clarify the role and duration of anticoagulant therapy in
these patients.
This study represents the largest national population-
based epidemiologic study in Asia that described the
management of VTE among cancer patients in Taiwan.
Our study found that the adherence to treatment
guidelines was poor in Taiwan. Long-term anticoagulant
therapy was only initiated in 64.1% of patients with VTE
(algorithm 2). In existing clinical guidelines, 3–6
months of LMWH are recommended for long-term
treatment of VTE in cancer patients [1,6,7,42]. However,
in our study, among patients who received long-term
treatment of VTE, LMWH was administered to only
9.6% of patients at anytime following the VTE events.
Most patients received warfarin monotherapy for the
long-term treatment of VTE. This is probably because
reimbursement for outpatient use of LMWH by NHI
was limited to pregnant patients with prosthetic valve
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duration of long-term anticoagulant therapy was
shorter than those recommended in clinical guidelines
[1,6,7,42].
Some limitations exist in the present study, generally
related to the use of a claims database. First, the actual
incidence of VTE may be underestimated, because some
patients with PE die suddenly without accurate diagno-
sis. Patients who treated in the outpatient clinic using
LMWH/oral anticoagulants were not included based on
our definitions. Identification of a VTE event based on
admission record may underestimate the incidence of
VTE. However, the magnitude of underestimation could
be very small as home injection of LMWH/UFH/fonda-
pariunx is not reimbursed under Taiwan’s National
Health Insurance system, cancer patients usually are ad-
mitted for receiving these treatments. In addition, as
patients usually receive LMWH/UFH for the initial
treatment of VTE (“incident” VTE in our study) and
warfarin for the long-term treatment, it is easier for phy-
sicians to monitor activated partial thromboplastin time
(aPTT) and international normalized ratio (INR) when
patients are hospitalized. These could be supported by
another epidemiological study of VTE in the Taiwanese
general population, in which the authors define their
VTE cases as those who admitted for a VTE event [19].
Furthermore, patients with asymptomatic VTE may not
be documented. We were unable to distinguish symp-
tomatic VTE and incidentally detected VTE as the infor-
mation were not routinely captured in a claim database.
However, our estimates provide the incidence rate of
clinically overt VTE, which is useful in helping decision
making of VTE prophylaxis in clinical practice. A second
limitation of our study is we identified our cancer cases
based on a diagnosis of cancer at hospitalization, cancer
cases diagnosed based on outpatient visit were not in-
cluded, which may underestimate the cancer population.
Nevertheless, as all NHI beneficiaries diagnosed with
cancer is required to have an confirmed cancer diagnosis
from the hospital to be eligible for a Certificate of Cata-
strophic Illness to be exempted from all co-payments,
cancer cases who only be treated in outpatient setting
are very few in Taiwan.
This approach could thus help us precisely identify the
cancer cases and avoid potential misclassifications.
Third, other factors that may contribute to development
of VTE, including disease stage, laboratory data and per-
formance status could not be obtained from the data-
bases. However, we include many variables such as
active therapy (e.g. radiation therapy) to serve as the
proxy of disease severity to reduce potential confound-
ing effects. Fourth, the study cohort may have received
anticoagulant treatment based on certain baseline and
prognostic characteristics. Finally, thromboprophylaxiscan alter the incidence of VTE, but its use in our study
population is unknown.
Conclusion
In conclusion, this retrospective cohort study describes
the epidemiology, risk factors, and clinical profile of VTE
across different types of cancer among an Asian popula-
tion. The incidence rate of VTE was higher among cancer
patients than among non-cancer patients in Taiwan but
lower than among Caucasian cancer patients. Clinical
practitioners should carefully monitor patients with can-
cer for VTE. Adherence to treatment guidelines was low
in this real world cohort of Taiwanese cancer patients with
VTE. Treatment and prophylaxis of VTE should be
optimized, especially in patients with higher-risk of VTE.
Due to the different epidemiologic profile of VTE in
Taiwan compared with Caucasian population, further in-
vestigations are desired to estimate the harms and benefits
of anticoagulants treatment and thromboprophylaxis
among Asian cancer patients.
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